PsiOxus Therapeutics has an advanced portfolio of products:
MT-102 is in phase II clinical development. It is a dual action Anabolic Catabolic Transforming Agent for the treatment of cancer cachexia and sarcopenia.
ColoAd1 is in late pre-clinical development. It is a chimeric oncolytic virus for the systemic treatment of metastatic cancer.
PolySTAR is a research phase vaccine platform. It combines recombinant viral vectors with polymers to shield them from the immune system.
PolyMAP is a research phase adjuvant and immunotherapeutic platform. It combines polymers with synthetic adjuvants to significantly enhance immunogenicity.